FBIO Fortress Biotech (FBIO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001429260
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
24
13F, latest reported quarter
Fortress Biotech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Fortress Biotech, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Jul 11, 2024.
- -8.4% median (-8.2% mean) 90-day return after 14 previous buys.
- The trade is 20.9% of the 3,657,264 shares held after it.
- No other insider bought within 30 days.
- 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT, CEO & CHAIRMAN ROSENWALD LINDSAY A MD bought about $1.4M of FBIO on Sep 23, 2024; 24 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Jul 9, 2024.
- -7.6% median (-7.4% mean) 90-day return after 13 previous buys.
- The trade is 3.9% of the 127,500 shares held after it.
- 1 other insider bought within 30 days.
- 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO & Chairman ROSENWALD LINDSAY A MD bought about $37.4K of FBIO on Jul 11, 2024; 1 other insider bought within 30 days and 24 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Feb 10, 2023.
- +5.7% median (+5.7% mean) 90-day return after 2 previous buys.
- The trade is 100.0% of the 500 shares held after it.
- 1 other insider bought within 30 days.
- 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Jin David bought about $3.8K of FBIO on Jul 10, 2024; 1 other insider bought within 30 days and 24 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Jul 8, 2024.
- -7.2% median (-7.3% mean) 90-day return after 12 previous buys.
- The trade is 4.1% of the 122,500 shares held after it.
- 1 other insider bought within 30 days.
- 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO & Chairman ROSENWALD LINDSAY A MD bought about $37.0K of FBIO on Jul 9, 2024; 1 other insider bought within 30 days and 24 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Jun 28, 2024.
- -5.3% median (-7.2% mean) 90-day return after 11 previous buys.
- The trade is 4.3% of the 117,500 shares held after it.
- 1 other insider bought within 30 days.
- 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO & Chairman ROSENWALD LINDSAY A MD bought about $36.8K of FBIO on Jul 8, 2024; 1 other insider bought within 30 days and 24 funds added in the latest 13F quarter.26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
24 funds bought in last quarter
below 65% of Pharma & Biotech
Revenue
+11.1% year over year
more than 60% of Pharma & Biotech
Margin
11.1% net margin
more than 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.8% of the float short (float per yahoo 2026-10-26) · 18.4 days to cover · settled 2026-09-30
more than 56% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FBIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-24.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FBIO: institutional holders (13F)
13F holdings, latest reported quarter
1,037,203 sh
$3.2M
890,000 sh
$2.7M
555,676 sh
$1.7M
300,521 sh
$919.9K
224,782 sh
$687.8K
Congress trades in FBIO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
FBIO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FBIO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$466.2K position · as of 2026-06-30
0.5%
iShares Micro-Cap ETF
$269.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$18.2K position · as of 2026-06-30
0.0%
Nomura Healthcare Fund
$20.4K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$856.5K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$366.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.9M
$3.6M
$1.6M
n/a
n/a
2024
$1.4M
$807.5K
$1.9M
n/a
n/a
2023
$1.1M
-$1.9M
$1.2M
n/a
n/a
2022
$1.3M
-$8.7M
$1.4M
-74%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 24 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FBIO financials
Revenue growth
+11.1%
XBRL, annual
Net margin
11.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$68.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM FBIO
| FY Dec 2025 | $63.3M |
| FY Dec 2024 | $57.7M |
| FY Dec 2023 | $84.5M |
| FY Dec 2022 | $75.7M |
| FY Dec 2021 | $68.8M |
| Jun 2026 | $18.7M |
| Mar 2026 | $16.0M |
| Dec 2025 | $16.1M |
| Sep 2025 | $17.6M |
| Jun 2025 | $16.4M |
| Mar 2025 | $13.1M |
| Dec 2024 | $15.1M |
| Sep 2024 | $14.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+207.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM FBIO
| FY Dec 2025 | +58.5% |
| FY Dec 2024 | +36.4% |
| FY Dec 2023 | +36.7% |
| FY Dec 2022 | -114.3% |
| FY Dec 2021 | -94.1% |
| Jun 2026 | -2.5% |
| Mar 2026 | +688.2% |
| Dec 2025 | +163.2% |
| Sep 2025 | +33.2% |
| Jun 2025 | +94.4% |
| Mar 2025 | -80.6% |
| Dec 2024 | +398.4% |
| Sep 2024 | -88.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM FBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$128.3M |
| FY Dec 2022 | -$182.1M |
| FY Dec 2021 | -$121.1M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$12.9M |
| Sep 2024 | -$20.1M |
At each fiscal year end
Single quarter
Debt to equity
0.21x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity FBIO
| FY Dec 2025 | 1.09x |
| FY Dec 2024 | 2.55x |
| FY Dec 2023 | 2.70x |
| FY Dec 2022 | 2.20x |
| FY Dec 2021 | 0.40x |
| Jun 2026 | 0.21x |
| Mar 2026 | 0.23x |
| Dec 2025 | 1.09x |
| Sep 2025 | 0.86x |
| Jun 2025 | 1.14x |
| Mar 2025 | 2.53x |
| Dec 2024 | 2.55x |
| Sep 2024 | 2.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
3.60x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt FBIO
| FY Dec 2025 | -1.21x |
| FY Dec 2024 | -1.38x |
| FY Dec 2023 | -2.11x |
| FY Dec 2022 | -1.96x |
| FY Dec 2021 | -2.71x |
| Jun 2026 | 3.60x |
| Mar 2026 | 4.20x |
| Dec 2025 | -1.21x |
| Sep 2025 | -1.38x |
| Jun 2025 | -1.60x |
| Mar 2025 | -1.32x |
| Dec 2024 | -1.38x |
| Sep 2024 | -1.95x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+136.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FBIO
| FY Dec 2025 | +101.9% |
| FY Dec 2024 | +92.8% |
| FY Dec 2023 | +96.5% |
| FY Dec 2022 | -115.1% |
| FY Dec 2021 | -61.9% |
| Jun 2026 | +136.5% |
| Mar 2026 | +171.3% |
| Dec 2025 | +101.9% |
| Sep 2025 | +184.3% |
| Jun 2025 | +169.1% |
| Mar 2025 | +114.1% |
| Dec 2024 | +92.8% |
| Sep 2024 | +228.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+59.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FBIO
| FY Dec 2025 | +22.4% |
| FY Dec 2024 | +13.5% |
| FY Dec 2023 | +13.4% |
| FY Dec 2022 | -25.1% |
| FY Dec 2021 | -17.7% |
| Jun 2026 | +59.6% |
| Mar 2026 | +59.1% |
| Dec 2025 | +22.4% |
| Sep 2025 | +46.0% |
| Jun 2025 | +34.2% |
| Mar 2025 | +15.1% |
| Dec 2024 | +13.5% |
| Sep 2024 | +31.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital FBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-16.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FBIO
| FY Dec 2025 | -67.5% |
| FY Dec 2024 | -141.9% |
| FY Dec 2023 | -114.2% |
| FY Dec 2022 | -88.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | -16.4% |
| Mar 2026 | -31.2% |
| Dec 2025 | -67.5% |
| Sep 2025 | -97.1% |
| Jun 2025 | -121.4% |
| Mar 2025 | -105.9% |
| Dec 2024 | -141.9% |
| Sep 2024 | -192.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.73x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing FBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 1.16x |
| Mar 2026 | 0.88x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$2.4M
market value at close 2026-10-23 on 2020-05-07 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value FBIO
| FY Dec 2025 | $277.0M |
| FY Dec 2024 | $168.1M |
| FY Dec 2023 | $228.2M |
| FY Dec 2022 | $730.0M |
| FY Dec 2021 | $2.8B |
| Jun 2026 | $90.8M |
| Mar 2026 | $11.8M |
| Dec 2025 | $277.0M |
| Sep 2025 | $266.7M |
| Jun 2025 | $129.0M |
| Mar 2025 | $93.7M |
| Dec 2024 | $168.1M |
| Sep 2024 | $113.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield FBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -51.7% |
| FY Dec 2022 | -22.3% |
| FY Dec 2021 | -3.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing FBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M |
| Operating income | -$70.2M | -$110.4M | -$142.3M | -$203.6M |
| Net income | $37.0M | $21.0M | $31.0M | -$86.6M |
| EPS (diluted) | -0.07 | -2.69 | -8.47 | -15.97 |
| Operating cash flow | -$65.8M | -$80.2M | -$128.2M | -$179.4M |
| Cash | $79.4M | $57.3M | $80.9M | $178.3M |
| Long-term debt | $54.5M | $58.0M | $60.9M | $91.7M |
| Dividends paid | $664.0K | $694.0K | $736.0K | $749.0K |
SEC XBRL, fiscal years, as known on 2026-10-27
FBIO Stock Sonar score 5/7 axes
Find similar shapesCompareFBIO ranks highest on profitability (90th percentile) and financial health (69th), and lowest on institutional and government (20th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
